NASDAQ:CTMX - CytomX Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CytomX Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.67 +0.97 (+14.48 %) (As of 03/31/2020 04:00 PM ET) Add Compare Today's Range$6.75Now: $7.67▼$7.8450-Day Range$3.61MA: $6.43▼$7.6252-Week Range$3.60Now: $7.67▼$12.63Volume769,100 shsAverage Volume446,931 shsMarket Capitalization$349.50 millionP/E RatioN/ADividend YieldN/ABeta0.82 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CTMX Previous Symbol CUSIPN/A CIK1501989 Webhttp://www.cytomx.com/ Phone650-515-3185Debt Debt-to-Equity Ratio0.49 Current Ratio3.54 Quick Ratio3.54Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$57.49 million Price / Sales6.08 Cash FlowN/A Price / Cash FlowN/A Book Value$1.12 per share Price / Book6.85Profitability EPS (Most Recent Fiscal Year)($2.26) Net Income$-102,240,000.00 Net Margins-177.84% Return on Equity-114.46% Return on Assets-26.15%Miscellaneous Employees137 Outstanding Shares45,567,000Market Cap$349.50 million Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive CTMX News and Ratings via Email Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CTMX Rates by TradingView CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions How has CytomX Therapeutics' stock been impacted by COVID-19 (Coronavirus)? CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CTMX shares have increased by 30.7% and is now trading at $7.67. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of CytomX Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CytomX Therapeutics. When is CytomX Therapeutics' next earnings date? CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for CytomX Therapeutics. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics Inc (NASDAQ:CTMX) announced its earnings results on Thursday, February, 27th. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.31. The biotechnology company had revenue of $8.28 million for the quarter, compared to analyst estimates of $15.69 million. CytomX Therapeutics had a negative net margin of 177.84% and a negative return on equity of 114.46%. View CytomX Therapeutics' earnings history. What price target have analysts set for CTMX? 8 brokerages have issued 1 year target prices for CytomX Therapeutics' shares. Their forecasts range from $7.00 to $23.00. On average, they anticipate CytomX Therapeutics' stock price to reach $14.14 in the next twelve months. This suggests a possible upside of 84.4% from the stock's current price. View analysts' price targets for CytomX Therapeutics. What are Wall Street analysts saying about CytomX Therapeutics stock? Here are some recent quotes from research analysts about CytomX Therapeutics stock: 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (3/9/2020) 2. Nomura analysts commented, "Progressing IO Probody CX-072—next steps 2H19: CX-072 (PD-L1) in combo with full dose ipi (3mg/kg) is well tolerated—plans for next phase of combo will be revealed in near future. We view undifferentiated pleomorphic sarcoma as offering potentially easier CX-072 combo differentiation vs ipi/PD- (L)1, where this combo has not been tolerated. Monotherapy next steps in 2H19, but based on single-arm expansion data, we still see oppy for monotherapy strategy (e.g., autoimmune disease pts/pts intolerant to PD-1). Solid tumor candidate Ph2 dose, indication: Ph2 registration-worthy? Recall, CTMX saw responses to CX- 2009 in solid-tumor pts including those who failed TROP2 from IMMU. CX- 2009 still in dose refinement, starting at 8mg/kg and using a modified toxicity probability interval (mTPI) design." (8/11/2019) 3. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Overweight rating and 12-month price target of $21/share. CytomX stock currently trades at an EV of ~$100M ($8.80/sh cash), and the shares are down about 27% YTD (vs. +8.5% for NBI), triggered by updates at its R&D day earlier this year. We believe that the company’s lead early-stage clinical assets, based on modified antibodies, are partially de-risked and are highly discounted at the current valuation. For CX-2009, we think that evolving clinical updates in the next 6-12 months should alleviate investor concerns about its safety profile and that risk of potential clinical setback is overstated." (5/13/2019) 4. HC Wainwright analysts commented, "We utilize a probability of approval of 70% for we employ a 10% discount rate, and a 29% effective tax rate, yielding a total value of $1.6B, or a price per share of $34, assuming 47.6M shares outstanding and roughly $329M in cash and equivalents as of end-4Q19." (4/3/2019) Has CytomX Therapeutics been receiving favorable news coverage? Headlines about CTMX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CytomX Therapeutics earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View the latest news aboutCytomX Therapeutics. Are investors shorting CytomX Therapeutics? CytomX Therapeutics saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 1,423,800 shares, an increase of 11.2% from the February 27th total of 1,280,000 shares. Based on an average trading volume of 465,800 shares, the short-interest ratio is currently 3.1 days. Currently, 3.2% of the company's stock are sold short. View CytomX Therapeutics' Current Options Chain. Who are some of CytomX Therapeutics' key competitors? Some companies that are related to CytomX Therapeutics include Tricida (TCDA), Innoviva (INVA), Ligand Pharmaceuticals (LGND), TG Therapeutics (TGTX), Madrigal Pharmaceuticals (MDGL), Heron Therapeutics (HRTX), I-Mab (ARQT), NextCure (NXTC), Amneal Pharmaceuticals (AMRX), Esperion Therapeutics (ESPR), Opko Health (OPK), Enanta Pharmaceuticals (ENTA), Aimmune Therapeutics (AIMT), Akebia Therapeutics (AKBA) and Supernus Pharmaceuticals (SUPN). What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX), Amicus Therapeutics (FOLD), AbbVie (ABBV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), Portola Pharmaceuticals (PTLA), Sorrento Therapeutics (SRNE) and Bristol-Myers Squibb (BMY). Who are CytomX Therapeutics' key executives? CytomX Therapeutics' management team includes the following people: Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)Mr. Debanjan Ray, Sr. VP & CFO (Age 41)Dr. Rachel Wallach Humphrey, Sr. VP & Chief Medical Officer (Age 58)Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)Dr. W. Michael Kavanaugh, Sr. VP, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63) What is CytomX Therapeutics' stock symbol? CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX." How do I buy shares of CytomX Therapeutics? Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CytomX Therapeutics' stock price today? One share of CTMX stock can currently be purchased for approximately $7.67. How big of a company is CytomX Therapeutics? CytomX Therapeutics has a market capitalization of $349.50 million and generates $57.49 million in revenue each year. The biotechnology company earns $-102,240,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. CytomX Therapeutics employs 137 workers across the globe. View additional information about CytomX Therapeutics. What is CytomX Therapeutics' official website? The official website for CytomX Therapeutics is http://www.cytomx.com/. How can I contact CytomX Therapeutics? CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected] MarketBeat Community Rating for CytomX Therapeutics (NASDAQ CTMX)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 327 (Vote Outperform)Underperform Votes: 257 (Vote Underperform)Total Votes: 584MarketBeat's community ratings are surveys of what our community members think about CytomX Therapeutics and other stocks. Vote "Outperform" if you believe CTMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTMX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: Sell-Side Analysts
